TITLE

Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity

AUTHOR(S)
Pagnani, Michelle
PUB. DATE
March 2012
SOURCE
Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.
ACCESSION #
74557350

 

Related Articles

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • VMA does not affect visual acuity after anti-VEGF injections for polypoidal choroidal vasculopathy. Kronemyer, Bob // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p26 

    The article reports that posterior vitreomacular adhesion (VMA) was not associated with visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopath based on a study led by ophthalmologist Dr. Han Joo Cho. Topics discussed include...

  • OPTIMAL MANAGEMENT OF NEOVASCULAR AMD: WHEN TO TREAT? WHAT TO TREAT? HOW TO TREAT?  // Johns Hopkins Advanced Studies in Ophthalmology;Nov2013, Vol. 10 Issue 3, p57 

    An introduction is presented in which the author discusses the advancement in diagnostic imaging and the strategies for treating age-related macular degeneration (AMD).

  • Sonepcizumab, anti-VEGF may yield long-term visual acuity. Charters, Lynda // Ophthalmology Times;11/15/2016, Vol. 41 Issue 19, p26 

    The article reports on the Nexus Study on the monoclonal antibody sonepcizumab and its effect of improving visual acuity and potential for long-term stabilization for patients diagnosed with age-related macular degeneration (AMD). Topics include the efficacy of sonepcizumab monotherapy and in...

  • Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome. Beykin, Gala; Grunin, Michelle; Averbukh, Edward; Banin, Eyal; Hemo, Yitzchak; Chowers, Itay // BMC Ophthalmology;2015, Vol. 15 Issue 1, p1 

    Background: To evaluate the long-term outcome of bevacizumab therapy for neovascular age related macular degeneration (NVAMD) in the setting of a clinic. Methods: Consecutive group of NVAMD patients who were treated in a single 3rd referral center with bevacizumab using a loading dosage of 3...

  • Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu, Figen; Demirel, Sibel; Ă–zmert, Emin; Abdullayev, Ahmet; Bilici, Serdar // BMC Ophthalmology;2015, Vol. 15 Issue 1, p1 

    Background: To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Methods: The study included patients who had been undergoing follow-up for a minimum of three months at the Ankara...

  • Novel therapy targets integrin receptors. Karageozian, Vicken // Ophthalmology Times;Oct2015, Vol. 40 Issue 17, p42 

    The article discusses the result of the clinical trial of ALG-1001 from Allegro Ophthalmics for the treatment of vitreoretinal disease. Topics covered include the comparability of ALG-1001 to that of anti-vascular endothelial growth factor agents, the reasons for targeting integrins in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics